Good afternoon :)
$
₹
I

Indivior PLC Ordinary Shares

INDV

NASDAQ
I

Indivior PLC Ordinary Shares

INDV

NASDAQ
$35.251.38% (+0.48)
$
₹
$35.251.38% (+0.48)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Mid Cap

With a market cap of $4.1B the stock is ranked 1626

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

12.26
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

145.24
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$2.83
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

26.75%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 4 analysts reports

Buy
4 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+39.01%

Earnings Growth

+79.22%

Rev. Growth

+7.5%

See Detailed Forecast

Company Profile

Company Profile

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.90
80.90
1Y Return
27.02%
27.02%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.82
27.82
1Y Return
55.96%
55.96%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
39.75%
39.75%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.73
29.73
1Y Return
29.43%
29.43%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.18
20.18
1Y Return
25.56%
25.56%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 39.01% growth, versus a trailing 3-year CAGR of 21.61%.

2026
Current$35.25Baseline
Analyst Target - 1 year
Target$49+39.01%

All values in $

202220232024202520262027$21.87$32.54$43.22Target+39.01%
2026
Current$35.25Baseline
Analyst Target - 1 year
Target$49+39.01%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 7.50% growth, versus a trailing 3-year CAGR of 11.20%.

2025
Current$1.23Baseline
Forecast for Dec 2026
High$1.34+8.27%
Average$1.33+7.5%
Low$1.31+6.38%

All values in $ Billion

2021202220232024202520260.790.901.091.181.23Low+6.38%Average+7.5%High+8.27%
2025
Current$1.23Baseline
Forecast for Dec 2026
High$1.34+8.27%
Average$1.33+7.5%
Low$1.31+6.38%

All values in $ Billion

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$2.46Baseline
Forecast for Dec 2026
High$4.47+81.71%
Average$4.41+79.22%
Low$4.36+77.24%

All values in $

2021202220232024202520261.31-0.441.561.162.46Low+77.24%Average+79.22%High+81.71%
2025
Current$2.46Baseline
Forecast for Dec 2026
High$4.47+81.71%
Average$4.41+79.22%
Low$4.36+77.24%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

314
42
358
102
316.9
88.9
343
122
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue284299307299266302314358316.99343
Net Income61-9745947184210288.99122
Net Profit Margin21.47%-32.44%1.30%19.73%17.66%5.96%13.37%28.49%28.07%35.56%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Indivior PLC Ordinary Shares 12.26145.24-
AbbVie Inc80.9050.450.58
Amgen Inc27.8220.562.65
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare INDV with any stock or ETF
Compare INDV with any stock or ETF
Comparing from
INDV
ABBV
AMGN
Loading...

Frequently asked questions

  1. Indivior PLC Ordinary Shares (INDV) share price today is $35.25 as of October 30, 2026 at 1:30 AM IST. The stock touched a day high of $36.71 and a day low of $34.55.

  2. Indivior PLC Ordinary Shares stock trades on NASDAQ under the ticker symbol INDV.

  3. Indivior PLC Ordinary Shares's market capitalization is $4.09B as of October 30, 2026 at 1:30 AM IST.

  4. Indivior PLC Ordinary Shares's price-to-earnings (P/E) ratio is 12.26 as of October 29, 2026.

  5. Indivior PLC Ordinary Shares's price-to-book (P/B) ratio is 145.24 as of October 29, 2026.

  6. Yes, You can buy Indivior PLC Ordinary Shares shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Indivior PLC Ordinary Shares shares in three steps: 1. Search Indivior PLC Ordinary Shares on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Indivior PLC Ordinary Shares trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Indivior PLC Ordinary Shares (INDV) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.2836 shares at the current price of $35.25.

Loading...